Witan Pacific Investment Trust (WPC); FY results: NAV per share falls 8.8%
Witan Pacific Investment Trust announced its results for the year ended 31 January 2019, showing that share price total return stood at -10.3%
Witan Pacific’s net assets stood at £220m (2018: £244m). Since 2005, Witan Pacific’s NAV total return of 218.7% compares favourably with the benchmark (215.7%).
Read more...Henderson Far East Income Limited (HFEL); half-year report: share price total return at -0.8%
Henderson Far East Income’s half year report ended 28 February 2019 showed that their NAV per share total return was -3.5% vs. a total return of the FTSE All-World Asia Pacific ex Japan of -3.7%
Henderson Far East Income Limited declared its unaudited results for the half year ended 28 February 2019. Henderson’s NAV per share total return was -3.5% vs. a total return of the FTSE All-World Asia Pacific ex Japan of -3.7%. Shares were trading at a premium of 2.1% at the period end.
Read more...ReNeuron Group (RENE); announces sustained and further improvement in first cohort of Phase 2a study
ReNeuron Group has announced that all three subjects in the first cohort of the Phase 2a element of human retinal progenitor cell (hRPC) therapy have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.
ReNeuron Group has announced that all three subjects in the first cohort of the Phase 2a element of human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.
Read more...Allied Minds (ALM); reports net profit of $47.3m for the year ended 31 December 2018
Allied Minds reported net profit of $47.3m for the year ended 31 December 2018 vs. net loss of $111.1m in 2017.
Allied Minds reported revenues of $5.6m in 2018 (2017: $5.0m), largely from non-recurring engineering (NRE) and service contracts, reflecting the early stage nature of the portfolio companies.
Read more...Findel (FDL); insufficient acceptances to enable Sports Direct offer
The board of Findel notes that the level of acceptances announced by Sports Direct International is insufficient to accept the offer. The company received additional valid acceptances representing only 0.01% of Findel's issued share capital after the first closing date of 09 April 2019
When integrated with Sports Direct’s existing holding of 36.84% of Findel’s issued share capital and the acceptances in respect of 0.98% of Findel’s issued share capital received at the first closing date, this totals ~37.83% of Findel’s shares that are either owned or for which valid acceptances have now been received. This level of acceptances is not sufficient to enable Sports Direct to declare its offer unconditional.
Read more...
Severfield (SFR); report year-end net funds at £25m
Overall trading performance in line with management's expectations
Severfield announced its trading update for the year ending 31 March 2019. The UK and European order book remains in line with normal levels at £274m, while the market for structural steel in India continues to improve, according to the company, with an order book of £149m as of 1 April 2019. The Indian joint venture also continued to perform well in H2, according to Severfield, with a growing pipeline, which includes a number of potential commercial projects, including various industrial opportunities, including those for the company’s joint venture partner, JSW Steel.
Read more...ICG-Longbow (LBOW); reports PAT at £5.26m for the FY ending 31 Jan 2019
ICG-Longbow reported an NAV of £120.28m in their final results for the year ending 31 January 2019.
ICG-Longbow reported an NAV of £120.28m in their final results for the year ending 31 January 2019. Total dividends were reported at 6p per share, while total income, excluding prepayment fees, stood at £7.64m.
Read more...Shield Therapeutics (STX); Swissmedic approves major extension of Feraccru in Switzerland
Shield Therapeutics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted a major extension of the approved indication for Feraccru®.
Shield Therapeutics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted a major extension of the approved indication for Feraccru to now include treatment of all adults with iron deficiency (ID) with or without anaemia.
Read more...WANdisco (WAND); preliminary results: reports revenue of $17.0m for the year
WANdisco reported revenue of $17.0m for the 2018 financial year (2017: $19.6m). Revenue for the second half of the year increased 13% to $11.3m.
WANdisco reported revenue of $17.0m for the 2018 financial year (2017: $19.6m). Revenue for the second half of the year increased 13% to $11.3m. That said, WANdisco reported both an adjusted EBITDA loss of $9.4m (2017: $0.6m) and an operating loss of $22.1m for 2018 (2017: $9.7m).
Read more...Supermarket Income (SUPR); acquires a Tesco supermarket; issues consideration shares
Supermarket Income announced the acquisition of a 90k sq ft. Tesco Extra supermarket in Mansfield, Nottinghamshire.
Supermarket Income announced the acquisition of a 90k sq ft. Tesco Extra supermarket in Mansfield, Nottinghamshire, from Charities Property Fund (CPF) for £45.0m, reflecting a net initial yield of 5.2%. The acquisition consists of £33.7m in cash, as well as the issue of 10,922,330 Supermarket Income new ordinary shares at 103p per share to CPF.
Read more...